Tranexamic acid competitively and reversibly Treating GI: diarrhea, nausea, Assessed for drug hypersensitivity Brand Name: inhibits the activation of CONTRAINDICATION: vomiting Observed the 10 Rs of drug Cyklokapron, Lysteda plasminogen via binding at Hypersensitivity to CV: Hypotension, administration THERAPEUTIC CLASS: several distinct sites, cephalosporins; Serious Thromboembolism, Assess for infection (vital signs; Hemostatic Agent including four or five low- hypersensitivity to penicillins. Thrombosis appearance of wound, sputum, Pharmacologic: affinity sites and one high- DRUG TO DRUG INTERACTION: EENT: Visual Abnormalities urine, and stool; WBC) at Antifibrinolytic Agents affinity site, the latter of Probenecid excretion and blood beginning and during therapy. which is involved in its levels of renally excreted Monitored site frequently for binding to fibrin. The binding cephalosporins. Concurrent thrombophlebitis Dosage ordered: of plasminogen to fibrin use of loop diuretics or Tx: 500 mg induces fibrinolysis - by aminoglycosides may Reconstitution drug varies by occupying the necessary risk of renal toxicity. size or package; see ROUTE: binding sites tranexamic acid manufacturer’s directions for IV prevents this dissolution of details fibrin, thereby stabilizing the Injected deep into a well- clot and preventing developed muscle mass; hemorrhage massage well. Therapeutic Effects: If aminoglycosides are Bactericidal action administered concurrently, against susceptible bacteria administer in separate sites, if possible, at least 1 hr apart. If second site is unavailable, flush line between medications. Edx: Advised patient to report signs of superinfection (furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools) and allergy. Instruct patient to notify health care professional if rash, or fever and diarrhea develop, especially if diarrhea contains blood, mucus, or pus. Advise patient not to treat diarrhea without consulting health care professional.